CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 257 enrolled
Drug / intervention
Enoxaparin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04401293
NCT04401293Phase 3Completed
CompareCT.gov

Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)

Northwell Health·interventional·Posted May 26, 2020·Updated Nov 22, 2021

In Brief

A Phase 3 clinical trial evaluating Enoxaparin and Prophylactic/Intermediate Dose Enoxaparin for Sars-CoV2 and COVID. Completed, enrolled 257 participants across 6 sites.

Detailed Summary

The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSars-CoV2, COVID
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedMay 26, 2020
Enrollment StartApr 26, 2020
Primary CompletionMay 14, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.1 years ago

Interventions

Enoxaparindrug

Full Dose LMWH anticoagulation therapy

Prophylactic/Intermediate Dose Enoxaparindrug

Prophylactic/Intermediate Dose LMWH or UFH therapy